https://www.nasdaq.com/press-release/biofrontera-ag-announces-mediation-results-2021-11-19
https://www.nasdaq.com/press-release/biofrontera-reports-financial-results-for-the-third-quarter-and-nine-months-ended
https://www.nasdaq.com/press-release/biofrontera-ag-announces-initiation-of-clinical-studies-2021-11-16
https://www.nasdaq.com/press-release/biofrontera-ag%3a-conference-call-to-discuss-third-quarter-2021-financial-results-to-be
https://www.nasdaq.com/press-release/biofrontera-ag-receives-fda-approval-of-the-bf-rhodoledr-xl-lamp-2021-10-22
https://www.nasdaq.com/press-release/biofrontera-reports-preliminary-approximate-revenues-for-the-month-of-september-2021
https://www.nasdaq.com/press-release/biofrontera-reports-preliminary-revenue-for-the-month-of-august-2021-2021-09-08
https://www.nasdaq.com/press-release/biofrontera-reports-financial-results-for-the-six-months-ended-june-30-2021-2021-08
https://www.nasdaq.com/press-release/biofrontera-ag%3a-conference-call-to-discuss-half-year-2021-financial-results-to-be
https://www.nasdaq.com/press-release/biofrontera-reports-preliminary-revenue-for-the-month-of-july-2021-2021-08-09
https://www.nasdaq.com/press-release/biofrontera-enters-into-license-and-supply-agreement-with-medac-for-the-marketing-of
https://www.nasdaq.com/press-release/biofrontera-inc.-seeks-ipo-in-the-usa-2021-07-06
https://www.nasdaq.com/press-release/biofrontera-reports-preliminary-revenue-for-the-month-of-june-2021-2021-07-06
https://www.nasdaq.com/press-release/biofrontera-provides-update-on-clinical-developments-2021-06-22
https://www.nasdaq.com/press-release/biofrontera-reports-preliminary-revenue-for-the-month-of-may-2021-2021-06-07
https://www.nasdaq.com/press-release/biofrontera-reports-q1-2021-financial-results-2021-05-11
https://www.nasdaq.com/press-release/biofrontera-reports-preliminary-revenue-for-the-month-of-april-2021-2021-05-06
https://www.nasdaq.com/press-release/biofrontera-ag%3a-first-quarter-conference-call-to-be-held-on-may-12-2021-2021-05-03
https://www.nasdaq.com/press-release/biofrontera-reports-results-for-the-2020-financial-year-2021-04-12
https://www.nasdaq.com/press-release/biofrontera-announces-preliminary-revenue-for-q1-2021-2021-04-08
https://www.nasdaq.com/press-release/biofrontera-announces-conference-call-to-be-held-on-april-13-2021-to-discuss-fiscal
https://www.nasdaq.com/press-release/biofrontera-submits-application-for-fda-approval-of-new-bf-rhodoledr-xl-lamp-2021-03
https://www.nasdaq.com/press-release/biofrontera-ag-announces-the-closing-of-the-capital-raise-with-gross-proceeds-of-eur
https://www.nasdaq.com/press-release/biofrontera-submits-study-report-of-pharmacokinetics-study-to-fda-2021-02-24
https://www.nasdaq.com/press-release/biofrontera-ag-announces-pricing-of-us%248.9-million-firm-commitment-public-offering-of
https://www.nasdaq.com/press-release/biofrontera-ag%3a-ludwig-lutter-appointed-new-chief-financial-officer-effective-march-1
https://www.nasdaq.com/press-release/biofrontera-announces-preliminary-revenue-figures-for-the-full-year-2020-2021-01-08
https://www.nasdaq.com/press-release/cologne-higher-regional-court-grants-approval-of-capital-increase-2021-01-07
https://www.nasdaq.com/press-release/biofrontera-enters-into-a-license-and-supply-agreement-with-galenica-ab-for-the
https://www.nasdaq.com/press-release/biofrontera-ag-resolves-mandatory-conversion-of-subordinated-mandatory-convertible
https://www.nasdaq.com/press-release/biofrontera-reports-third-quarter-and-first-nine-months-2020-results-2020-11-11
https://www.nasdaq.com/press-release/biofrontera-announces-conference-call-to-be-held-on-november-12-2020-to-discuss-q3
https://www.nasdaq.com/press-release/biofrontera-ag%3a-receives-reasons-from-the-federal-court-of-justice-for-overturning
https://www.nasdaq.com/press-release/biofrontera-reports-preliminary-unaudited-sales-revenue-for-the-third-quarter-of-2020
https://www.nasdaq.com/press-release/biofrontera-ag-reports-completion-of-the-clinical-phase-of-the-pharmacokinetics-study
https://www.nasdaq.com/press-release/biofrontera-ag%3a-german-federal-supreme-court-overturns-ruling-of-the-cologne-higher
https://www.nasdaq.com/press-release/biofrontera-ag-plans-mediation-to-resolve-legal-disputes-2020-09-11
https://www.nasdaq.com/press-release/biofrontera-ag-to-participate-in-two-upcoming-conferences-2020-09-09
https://www.nasdaq.com/press-release/biofrontera-report-results-for-the-first-six-months-of-2020-2020-08-26
https://www.nasdaq.com/press-release/admission-to-trading-of-biofronteras-1.00-qualified-subordinated-mandatory
https://www.nasdaq.com/press-release/biofrontera-announces-conference-call-to-be-held-on-august-27-2020-to-discuss-half
https://www.nasdaq.com/press-release/capital-measure-oversubscribed%3a-placement-of-the-1.00-qualified-subordinated
https://www.nasdaq.com/press-release/result-of-the-subscription-of-the-1.00-qualified-subordinated-mandatory-convertible
https://www.nasdaq.com/press-release/biofrontera-ag-announces-subscription-price-for-1.00-qualified-subordinated-mandatory
https://www.nasdaq.com/press-release/biofrontera-ag-resolves-to-issue-qualified-subordinated-mandatory-convertible-bonds-0
https://www.nasdaq.com/press-release/supervisory-board-of-biofrontera-ag-renews-management-board-appointment-2020-07-23
https://www.nasdaq.com/press-release/biofrontera-reports-preliminary-unaudited-sales-revenue-for-the-first-six-months-of
https://www.nasdaq.com/press-release/results-of-the-2020-annual-general-meeting-of-biofrontera-ag-2020-05-28
https://www.nasdaq.com/press-release/biofrontera-reports-q1-2020-financial-results-2020-05-19
https://www.nasdaq.com/press-release/biofrontera-dismisses-case-against-dusa-pharmaceuticals-inc.-in-california-state
https://www.nasdaq.com/press-release/biofrontera-announces-conference-call-to-be-held-on-may-20-2020-to-discuss-first
https://www.nasdaq.com/press-release/biofrontera-reports-full-year-2019-financial-results-2020-04-20
https://www.nasdaq.com/press-release/biofrontera-ag-enters-into-exclusive-license-agreement-with-maruho-co.-ltd.-2020-04
https://www.nasdaq.com/press-release/biofrontera-reports-preliminary-unaudited-sales-revenue-for-the-first-three-months-of
https://www.nasdaq.com/press-release/biofrontera-ag-to-propose-resolution-for-ordinary-capital-increase-to-the-annual
https://www.nasdaq.com/press-release/biofrontera-announces-conference-call-to-be-held-on-april-21-2020-to-discuss-full
https://www.nasdaq.com/press-release/biofrontera-ag-withdraws-subscription-offers-for-mandatory-convertible-bonds-2020-03
https://www.nasdaq.com/press-release/biofrontera-implements-comprehensive-measures-to-reduce-costs-during-covid-19
https://www.nasdaq.com/press-release/biofrontera-ag-signs-non-binding-term-sheet-for-licensing-agreement-for-ameluzr-in
https://www.nasdaq.com/press-release/biofrontera-ag-extends-subscription-period-for-mandatory-convertible-bonds-2020-03-12
https://www.nasdaq.com/press-release/european-commission-approves-use-of-ameluzr-for-the-treatment-of-actinic-keratosis-on
https://www.nasdaq.com/press-release/biofrontera-entered-into-binding-term-sheet-with-maruho-co.-ltd.-2020-03-03
https://www.nasdaq.com/press-release/biofrontera-ag-resolves-to-issue-qualified-subordinated-mandatory-convertible-bonds
https://www.nasdaq.com/press-release/biofrontera-provides-clinical-development-updates-2020-02-19
https://www.nasdaq.com/press-release/european-medicines-agency-recommends-indication-expansion-of-ameluzr-for-treatment-of
https://www.nasdaq.com/press-release/organizational-restructuring-of-biofrontera-and-resignation-of-chief-commercial
https://www.nasdaq.com/press-release/biofrontera-announces-1-year-follow-up-results-for-its-phase-iii-study-of
https://www.nasdaq.com/press-release/biofrontera-announces-preliminary-sales-figures-for-the-full-year-2019-record-sales
https://www.nasdaq.com/press-release/biofrontera-strengthens-commercial-focus-with-reorganization-of-its-us-business-2020
https://www.nasdaq.com/press-release/extraordinary-general-meeting-of-biofrontera-ag%3a-biofrontera-management-board
https://www.nasdaq.com/press-release/christopher-pearson-appointed-new-chief-commercial-officer-at-us-subsidiary
https://www.nasdaq.com/press-release/biofrontera-to-participate-in-upcoming-investor-conferences-2019-11-22
https://www.nasdaq.com/press-release/biofrontera-reports-third-quarter-2019-financial-results-and-revises-guidance-2019-11
https://www.nasdaq.com/press-release/biofrontera-announces-conference-call-on-november-19-2019-to-discuss-third-quarter
https://www.nasdaq.com/press-release/biofrontera-receives-award-at-fall-clinical-dermatology-conference-2019-2019-10-23
https://www.nasdaq.com/press-release/biofrontera-reports-preliminary-unaudited-sales-revenue-for-the-first-nine-months-of
